Europe, Japan, and US Align on Antibiotics
The three regulatory agencies have agreed to data requirements for development of new antibiotics.
The European Medicines Agency (EMA) announced on June 12, 2017 that EMA, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), and the US FDA were aligning their data requirements for clinical development of new antibiotics. The agencies will also be updating relative guidance documents and providing drug developers with advice.
The alignment follows meetings held in September 2016 and April 2017 where the agencies discussed their approaches to the development and evaluation of antibiotics. The April 2017 meeting specifically discussed the design of clinical trials to test new treatments, particularly those against drug-resistant organisms.
“Stimulating and facilitating the development of new antibiotics, in particular those targeting multidrug-resistant pathogens, is one of the three pillars in EMA’s approach and European Commission's priorities to fight antimicrobial resistance,” EMA stated in a press release.
Source: EMA
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
